TapewireFind a company

person · Reporting owner

Ballal Rahul D.

Disclosed activity across 2 companies

Tapewire entity
35999
SEC CIK
0001805097

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499DirectorJune 18, 2026June 23, 2026
Enliven Therapeutics, Inc.ELVN · Entity 4024DirectorFebruary 12, 2026February 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AGIOS PHARMACEUTICALS, INC.

Report date June 18, 2026 · Filed June 23, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common stockSEC Table I · non-derivativeDirect15,230 Reported balance After 2026-06-18 transaction · row 1
1 source row

Row 1 · 2026-06-18 · Exercise / conversion · Acquired 2,816 · Balance 15,230

Restricted stock unitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-06-18 · Exercise / conversion · Disposed 2,816 · Balance 0

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Restricted stock unitsSEC Table II · derivative / convertible securityDirect2,927 Reported balance After 2026-06-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-06-18 · Grant · Acquired 2,927 · Balance 2,927

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2036-06-18Direct14,950 Reported balance After 2026-06-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-06-18 · Grant · Acquired 14,950 · Balance 14,950

F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Enliven Therapeutics, Inc.

Report date February 12, 2026 · Filed February 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.16 · Expires 2036-02-12Direct17,126 Reported balance After 2026-02-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-02-12 · Grant · Acquired 17,126 · Balance 17,126

F1: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 18, 2026 Filed Jun 23, 2026 21:25 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 GrantStock options (right to buy) · Derivative 14,950 $0.00 Strike: $34.16 $0.00
Disclosure

SEC source: 0001439222-26-000107 · wk-form4_1782249916.xml · derivative · entry 4

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,950

Underlying: Common stock · 14,950 shares

Expires 2036-06-18

F4 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:25 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 GrantRestricted stock units · Derivative 2,927 $0.00 $0.00
Disclosure

SEC source: 0001439222-26-000107 · wk-form4_1782249916.xml · derivative · entry 3

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,927

Underlying: Common stock · 2,927 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F3 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F3 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:25 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionRestricted stock units · Derivative 2,816 $0.00 $0.00
Disclosure

SEC source: 0001439222-26-000107 · wk-form4_1782249916.xml · derivative · entry 2

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 2,816 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:25 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionCommon stock 2,816 $0.00 $0.00
Disclosure

SEC source: 0001439222-26-000107 · wk-form4_1782249916.xml · nonDerivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,230

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 12, 2026 Filed Feb 18, 2026 00:55 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 GrantStock Option (right to buy) · Derivative 17,126 $0.00 Strike: $27.16 $0.00
Disclosure

SEC source: 0001805097-26-000001 · form4-02182026_120215.xml · derivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,126

Underlying: Common Stock · 17,126 shares

Expires 2036-02-12

F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.

Read SEC document
August 11, 2025 Filed Aug 13, 2025 20:55 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionRestricted stock units · Derivative 2,302 $0.00 $0.00
Disclosure

SEC source: 0001439222-25-000098 · wk-form4_1755118547.xml · derivative · entry 2

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 2,302 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.

F2 · derivative.expiration_date: The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.

Read SEC document
August 11, 2025 Filed Aug 13, 2025 20:55 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionCommon stock 2,302 $0.00 $0.00
Disclosure

SEC source: 0001439222-25-000098 · wk-form4_1755118547.xml · nonDerivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,414

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 20, 2025 Filed Jun 23, 2025 20:27 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionRestricted stock units · Derivative 2,120 $0.00 $0.00
Disclosure

SEC source: 0001439222-25-000061 · wk-form4_1750710427.xml · derivative · entry 4

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 2,120 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F4 · derivative.exercise_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F4 · derivative.expiration_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Read SEC document
June 20, 2025 Filed Jun 23, 2025 20:27 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionCommon stock 2,120 $0.00 $0.00
Disclosure

SEC source: 0001439222-25-000061 · wk-form4_1750710427.xml · nonDerivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 18, 2025 Filed Jun 23, 2025 20:27 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 GrantStock options (right to buy) · Derivative 15,768 $0.00 Strike: $35.50 $0.00
Disclosure

SEC source: 0001439222-25-000061 · wk-form4_1750710427.xml · derivative · entry 3

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,768

Underlying: Common stock · 15,768 shares

Expires 2035-06-18

F3 · derivative.exercise_date: These options were granted on June 18, 2025. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2026.

Read SEC document
June 18, 2025 Filed Jun 23, 2025 20:27 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 GrantRestricted stock units · Derivative 2,816 $0.00 $0.00
Disclosure

SEC source: 0001439222-25-000061 · wk-form4_1750710427.xml · derivative · entry 2

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,816

Underlying: Common stock · 2,816 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Read SEC document
February 06, 2025 Filed Feb 10, 2025 22:33 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 GrantStock Option (right to buy) · Derivative 20,491 $0.00 Strike: $22.47 $0.00
Disclosure

SEC source: 0001415889-25-003516 · form4-02102025_100220.xml · derivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,491

Underlying: Common Stock · 20,491 shares

Expires 2035-02-06

F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2025 annual meeting of the Issuer's stockholders or (ii) the date of the 2026 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date.

Read SEC document
November 08, 2024 Filed Nov 12, 2024 21:09 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionStock option (right to buy) · Derivative 10,000 $0.00 Strike: $25.99 $0.00
Disclosure

SEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · derivative · entry 9

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,947

Underlying: Common stock · 10,000 shares

Expires 2032-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F7 · derivative.exercise_date: This option was granted on August 11, 2022. The shares underlying this option vest as to 25% of the underlying shares on August 11, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Read SEC document
November 08, 2024 Filed Nov 12, 2024 21:09 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 SaleCommon stock 1,500 $59.21 $88,815.00
Disclosure

SEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · nonDerivative · entry 7

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,992

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $59.01 to $59.37. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
November 08, 2024 Filed Nov 12, 2024 21:09 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 SaleCommon stock 4,929 $58.57 $288,691.53
Disclosure

SEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · nonDerivative · entry 6

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,492

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $58.00 to $58.99. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
November 08, 2024 Filed Nov 12, 2024 21:09 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 SaleCommon stock 3,571 $57.24 $204,404.04
Disclosure

SEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · nonDerivative · entry 5

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,421

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $57.00 to $58.00. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
November 08, 2024 Filed Nov 12, 2024 21:09 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionCommon stock 10,000 $25.99 $259,900.00
Disclosure

SEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · nonDerivative · entry 4

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,992

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Read SEC document
November 07, 2024 Filed Nov 12, 2024 21:09 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionStock option (right to buy) · Derivative 10,000 $0.00 Strike: $25.99 $0.00
Disclosure

SEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · derivative · entry 8

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,947

Underlying: Common stock · 10,000 shares

Expires 2032-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F7 · derivative.exercise_date: This option was granted on August 11, 2022. The shares underlying this option vest as to 25% of the underlying shares on August 11, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Read SEC document
November 07, 2024 Filed Nov 12, 2024 21:09 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 SaleCommon stock 1,868 $54.41 $101,637.88
Disclosure

SEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · nonDerivative · entry 3

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,992

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $54.02 to $54.60. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
November 07, 2024 Filed Nov 12, 2024 21:09 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 SaleCommon stock 8,132 $53.32 $433,598.24
Disclosure

SEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · nonDerivative · entry 2

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,860

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $53.00 to $53.84. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
November 07, 2024 Filed Nov 12, 2024 21:09 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionCommon stock 10,000 $25.99 $259,900.00
Disclosure

SEC source: 0001439222-24-000142 · wk-form4_1731445769.xml · nonDerivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,992

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Read SEC document
October 08, 2024 Filed Oct 11, 2024 00:36 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionStock Option (right to buy) · Derivative 4,106 $0.00 Strike: $5.52 $0.00
Disclosure

SEC source: 0001415889-24-024990 · form4-10112024_121018.xml · derivative · entry 5

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,322

Underlying: Common Stock · 4,106 shares

Expires 2032-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F4 · derivative.exercise_date: The option, originally for 32,849 shares, vested as to one-fourth of the shares on January 28, 2023, and the remainder of the shares vest in 12 equal quarterly installments thereafter.

Read SEC document
October 08, 2024 Filed Oct 11, 2024 00:36 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionStock Option (right to buy) · Derivative 6,314 $0.00 Strike: $19.68 $0.00
Disclosure

SEC source: 0001415889-24-024990 · form4-10112024_121018.xml · derivative · entry 4

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,428

Underlying: Common Stock · 6,314 shares

Expires 2029-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Read SEC document
October 08, 2024 Filed Oct 11, 2024 00:36 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 SaleCommon Stock 10,420 $28.17 $293,557.45
Disclosure

SEC source: 0001415889-24-024990 · form4-10112024_121018.xml · nonDerivative · entry 3

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,341

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $28.00 to $28.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
October 08, 2024 Filed Oct 11, 2024 00:36 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionCommon Stock 4,106 $5.52 $22,665.12
Disclosure

SEC source: 0001415889-24-024990 · form4-10112024_121018.xml · nonDerivative · entry 2

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,761

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

Read SEC document
October 08, 2024 Filed Oct 11, 2024 00:36 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionCommon Stock 6,314 $19.68 $124,259.52
Disclosure

SEC source: 0001415889-24-024990 · form4-10112024_121018.xml · nonDerivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,655

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

Read SEC document
August 11, 2024 Filed Aug 13, 2024 20:15 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionRestricted stock units · Derivative 2,302 $0.00 $0.00
Disclosure

SEC source: 0001439222-24-000127 · wk-form4_1723580129.xml · derivative · entry 2

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,302

Underlying: Common stock · 2,302 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.

F2 · derivative.expiration_date: The restricted stock units were granted on August 11, 2022. Beginning on August 11, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.

Read SEC document
August 11, 2024 Filed Aug 13, 2024 20:15 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionCommon stock 2,302 $0.00 $0.00
Disclosure

SEC source: 0001439222-24-000127 · wk-form4_1723580129.xml · nonDerivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,992

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 20, 2024 Filed Jun 24, 2024 20:10 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 GrantStock options (right to buy) · Derivative 11,774 $0.00 Strike: $42.45 $0.00
Disclosure

SEC source: 0001439222-24-000106 · wk-form4_1719259815.xml · derivative · entry 2

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,774

Underlying: Common stock · 11,774 shares

Expires 2034-06-20

F3 · derivative.exercise_date: This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025.

Read SEC document
June 20, 2024 Filed Jun 24, 2024 20:10 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 GrantRestricted stock units · Derivative 2,120 $0.00 $0.00
Disclosure

SEC source: 0001439222-24-000106 · wk-form4_1719259815.xml · derivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,120

Underlying: Common stock · 2,120 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F2 · derivative.expiration_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Read SEC document
June 13, 2024 Filed Jun 17, 2024 21:22 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionRestricted stock units · Derivative 3,388 $0.00 $0.00
Disclosure

SEC source: 0001439222-24-000085 · wk-form4_1718659363.xml · derivative · entry 2

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 3,388 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F2 · derivative.expiration_date: The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Read SEC document
June 13, 2024 Filed Jun 17, 2024 21:22 UTC AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 Exercise / conversionCommon stock 3,388 $0.00 $0.00
Disclosure

SEC source: 0001439222-24-000085 · wk-form4_1718659363.xml · nonDerivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,690

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 11, 2024 Filed Apr 12, 2024 22:23 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionStock Option (right to buy) · Derivative 4,580 $0.00 Strike: $19.68 $0.00
Disclosure

SEC source: 0001415889-24-010777 · form4-04122024_100442.xml · derivative · entry 10

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,742

Underlying: Common Stock · 4,580 shares

Expires 2029-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F6 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Read SEC document
April 11, 2024 Filed Apr 12, 2024 22:23 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionStock Option (right to buy) · Derivative 48,820 $0.00 Strike: $12.60 $0.00
Disclosure

SEC source: 0001415889-24-010777 · form4-04122024_100442.xml · derivative · entry 9

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 48,820 shares

Expires 2028-10-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F6 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Read SEC document
April 11, 2024 Filed Apr 12, 2024 22:23 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 SaleCommon Stock 3,068 $25.21 $77,342.44
Disclosure

SEC source: 0001415889-24-010777 · form4-04122024_100442.xml · nonDerivative · entry 7

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,341

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F5 · price: This transaction was executed in multiple trades at prices ranging from $25.02 to $25.485. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
April 11, 2024 Filed Apr 12, 2024 22:23 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 SaleCommon Stock 20,032 $25.00 $500,701.84
Disclosure

SEC source: 0001415889-24-010777 · form4-04122024_100442.xml · nonDerivative · entry 6

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,409

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F4 · price: This transaction was executed in multiple trades at prices ranging from $24.015 to $25.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
April 11, 2024 Filed Apr 12, 2024 22:23 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 SaleCommon Stock 30,300 $23.14 $701,023.83
Disclosure

SEC source: 0001415889-24-010777 · form4-04122024_100442.xml · nonDerivative · entry 5

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,441

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $23.00 to $23.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
April 11, 2024 Filed Apr 12, 2024 22:23 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionCommon Stock 4,580 $19.68 $90,134.40
Disclosure

SEC source: 0001415889-24-010777 · form4-04122024_100442.xml · nonDerivative · entry 4

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,741

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

Read SEC document
April 11, 2024 Filed Apr 12, 2024 22:23 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionCommon Stock 48,820 $12.60 $615,132.00
Disclosure

SEC source: 0001415889-24-010777 · form4-04122024_100442.xml · nonDerivative · entry 3

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,161

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

Read SEC document
April 10, 2024 Filed Apr 12, 2024 22:23 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionStock Option (right to buy) · Derivative 13,600 $0.00 Strike: $12.60 $0.00
Disclosure

SEC source: 0001415889-24-010777 · form4-04122024_100442.xml · derivative · entry 8

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,820

Underlying: Common Stock · 13,600 shares

Expires 2028-10-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F6 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Read SEC document
April 10, 2024 Filed Apr 12, 2024 22:23 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 SaleCommon Stock 13,600 $21.01 $285,744.16
Disclosure

SEC source: 0001415889-24-010777 · form4-04122024_100442.xml · nonDerivative · entry 2

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,341

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $21.00 to $21.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
April 10, 2024 Filed Apr 12, 2024 22:23 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionCommon Stock 13,600 $12.60 $171,360.00
Disclosure

SEC source: 0001415889-24-010777 · form4-04122024_100442.xml · nonDerivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,941

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

Read SEC document
April 04, 2024 Filed Apr 9, 2024 00:40 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionStock Option (right to buy) · Derivative 3,485 $0.00 Strike: $12.60 $0.00
Disclosure

SEC source: 0001415889-24-010520 · form4-04092024_120438.xml · derivative · entry 3

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,420

Underlying: Common Stock · 3,485 shares

Expires 2028-10-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Read SEC document
April 04, 2024 Filed Apr 9, 2024 00:40 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 SaleCommon Stock 3,485 $19.15 $66,729.39
Disclosure

SEC source: 0001415889-24-010520 · form4-04092024_120438.xml · nonDerivative · entry 2

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,341

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $19.05 to $19.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
April 04, 2024 Filed Apr 9, 2024 00:40 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionCommon Stock 3,485 $12.60 $43,911.00
Disclosure

SEC source: 0001415889-24-010520 · form4-04092024_120438.xml · nonDerivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,826

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

Read SEC document
April 01, 2024 Filed Apr 4, 2024 01:32 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionStock Option (right to buy) · Derivative 3,143 $0.00 Strike: $5.52 $0.00
Disclosure

SEC source: 0001415889-24-010232 · form4-04042024_010458.xml · derivative · entry 5

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,428

Underlying: Common Stock · 3,143 shares

Expires 2032-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F5 · derivative.exercise_date: The option, originally for 32,849 shares, which share amount reflects the Stock Split, vested as to one-fourth of the shares on January 28, 2023, and the remainder of the shares vest in 12 equal quarterly installments thereafter.

F4 · balance_after: The number of shares beneficially owned reflect the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the "Stock Split").

Read SEC document
April 01, 2024 Filed Apr 4, 2024 01:32 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionStock Option (right to buy) · Derivative 94 $0.00 Strike: $12.60 $0.00
Disclosure

SEC source: 0001415889-24-010232 · form4-04042024_010458.xml · derivative · entry 4

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,905

Underlying: Common Stock · 94 shares

Expires 2028-10-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof.

F4 · balance_after: The number of shares beneficially owned reflect the 1-for-4 reverse stock split of the Issuer's Common Stock effected February 23, 2023 (the "Stock Split").

Read SEC document
April 01, 2024 Filed Apr 4, 2024 01:32 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 SaleCommon Stock 3,237 $19.08 $61,758.40
Disclosure

SEC source: 0001415889-24-010232 · form4-04042024_010458.xml · nonDerivative · entry 3

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,341

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $19.00 to $19.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
April 01, 2024 Filed Apr 4, 2024 01:32 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionCommon Stock 3,143 $5.52 $17,349.36
Disclosure

SEC source: 0001415889-24-010232 · form4-04042024_010458.xml · nonDerivative · entry 2

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,578

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

Read SEC document
April 01, 2024 Filed Apr 4, 2024 01:32 UTC Enliven Therapeutics, Inc. ELVN · Entity 4024 Exercise / conversionCommon Stock 94 $12.60 $1,184.40
Disclosure

SEC source: 0001415889-24-010232 · form4-04042024_010458.xml · nonDerivative · entry 1

Ballal Rahul D. · CIK 0001805097 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,435

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.